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Background: Atherosclerosis and psoriasis (PS) are chronic inflammatory diseases that exhibit epidemiological, immunopathological and clinical 
similarities. Although results have suggested that PS may be an independent risk factor for myocardial infarction, the significance of PS for the risk of 
atrial fibrillation (AFIB) and stroke is unclear.
Methods: The study population comprised the entire Danish population aged > 10 years on January 1th 1997 (n = 4,614,840) and subjects 
were followed until December 31th 2006 or death. Patients with incident PS were identified by individual-level-linkage of nationwide administrative 
registers of hospitalizations and claimed drug prescriptions. Incident PS was identified by the first use of topical vitamin-D prescriptions. Patients 
undergoing continuous hospital-based PS treatment were classified as having moderate/severe PS. Risk of AFIB and stroke was analyzed by time-
dependent Poisson regression models. A subgroup analysis in patients aged < 50 years at study entry was made.
Results: A total of 40,262 patients with incident PS were identified and stratified as having mild (n = 38,774) or moderate/severe PS (n=2,854). 
The mean age at entry was 46.4 years for mild PS (49.8% men) 44.3 years for moderate/severe PS (51.3% men), and 44.2 years for controls 
without PS (49,1% men). PS was associated with increased risk of AFIB for both mild PS (RR 1.22; CI 1.08-1.37) and moderate/severe PS (RR 1.51; 
CI 1.28-1.79). Mild PS (RR 1.19; CI 1.07-1.33) and moderate/severe PS (RR 1.45; CI 1.24-1.70) were also associated with increased risk of stroke. 
The increased risks of AFIB and stroke were age-dependent, e.g., RR 2,28 (CI 1.54-3.39) and RR 1.92 (CI 1.38-2.65), respectively, in patients with 
moderate/severe PS aged <50 years at study entry.
Conclusions: This nationwide study shows that PS is a risk factor for AFIB and stroke, and that this risk is aggravated in young patients. To our 
knowledge, the observed association between PS and AFIB is novel, and the results suggest that PS patients should be subjected to aggressive 
cardiovascular risk factor modification.
